Inhibition of autophagy enhances the selective anti-cancer activity of tigecycline to overcome drug resistance in the treatment of chronic myeloid leukemia

BACKGROUND: Drug resistance and disease progression are still the major obstacles in the treatment of chronic myeloid leukemia (CML). Increasing researches have demonstrated that autophagy becomes activated when cancer cells are subjected to chemotherapy, which is involved in the development of drug...

Descripción completa

Detalles Bibliográficos
Autores principales: Lu, Ziyuan, Xu, Na, He, Bolin, Pan, Chengyun, Lan, Yangqing, Zhou, Hongsheng, Liu, Xiaoli
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2017
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5345227/
https://www.ncbi.nlm.nih.gov/pubmed/28283035
http://dx.doi.org/10.1186/s13046-017-0512-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5345227/
https://www.ncbi.nlm.nih.gov/pubmed/28283035
http://dx.doi.org/10.1186/s13046-017-0512-6

Ejemplares similares